Today announced that it has raised $16 million in the original close of a Series C funding.

Remon plans to use the money to expand its presence in the U.S. And continue the development of its product portfolio, through its Israeli R&D subsidiary. The technology is normally integrated into minute implants, requiring no antenna, cables, or connecting leads, enabling a little device implanted deep inside the body to communicate wirelessly with other implanted gadgets and external systems. These devices monitor a variety of physiological parameters or stimulate organs and tissues or activate other gadgets, creating therapeutic responses. Remon intends to commercialize its product through internal efforts and strategic collaborations with world-leading partners. Remon Medical has finished the enrollment for its medical trial of the Remon ImpressureTM, a gadget that provides on-demand, noninvasive means to monitor intra-aneurysm pressures following endo-vascular graft procedures.Previous studies have discovered that moderate drinking can reduce dangers for vascular death and disease, said Dr. Alison Moore, associate professor of geriatrics at the David Geffen School of Medicine at UCLA, and the research's lead researcher. None of these studies have specifically viewed the interaction of alcoholic beverages use and conditions or medications which may be unsafe with even moderate amounts of alcohol use, she said. This research shows that while moderate alcoholic beverages use may be fine for people who don't have other conditions that could be worsened by the use of alcohol, such alcoholic beverages use might not be fine invest the common medications for rest, or for arthritis pain, or have depression, or involve some gastrointestinal condition.